Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations
Researchers determined that gPALB2 may be a promising biomarker for talazoparib response.
Diagnosis & Disease Information
Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
Can BRCA-Positive Patients With Breast Cancer Safely Become Pregnant?
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
OS Benefit of Adding Atezolizumab to Nab-Paclitaxel for Patients With Advanced, PD-L1–Positive Triple-Negative Breast Cancer
Rates of 2-year OS were 51% and 37% in the subgroup of patients with detectable tumor levels of PD-L1 who received atezolizumab and placebo, respectively.
Neratinib Improved PFS Compared With Lapatinib in Pretreated HER2-Positive Metastatic Breast Cancer
Rates of grade 3 diarrhea were 2-fold higher for patient receiving neratinib vs lapatinib, although fewer patients discontinued neratinib due to a treatment-related AE.
Improved PFS for Pyrotinib Plus Capecitabine vs Placebo Plus Capecitabine in Trastuzumab-Pretreated Metastatic HER2-Positive Breast Cancer
Antitumor activity was also observed in the subgroup of patients receiving pyrotinib monotherapy following disease progression on placebo plus capecitabine.
OS Improvement With Addition of CDK4/6 Inhibitor to Endocrine Therapy in Younger Women With Metastatic Breast Cancer
This is the first study to demonstrate a statistically significant improvement in OS with the addition of a CDK4/6 inhibitor to endocrine therapy.
HER2 Intratumor Heterogeneity as a Biomarker of Nonresponse to Neoadjuvant Dual HER2-Targeted Therapy in HER2-Positive Breast Cancer
Evidence of HER2 intratumor heterogeneity was found in 10% of the patients enrolled in this study.
Margetuximab Improved PFS Compared With Trastuzumab in Pretreated Metastatic HER2-Positive Breast Cancer
The Fc fragment of therapeutic antibodies is believed to recognize specific receptors on immune cells and mediate immune functions through this interaction.
No Link Found Between HRD and Pathologic Response in Triple-Negative Breast Cancer
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
- Loading...
Loading...
Next post in ASCO 2019 Breast Cancer In Depth
Loading... 
Loading...